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Background: Among a variety of inflammatory mediators, visfatin is a proinflammatory adipocytokine associated
with inflammatory reactions in obesity, metabolic syndrome, chronic inflammatory disease, and autoimmune
disease. However, the biological role of visfatin in secretion of major mucins in human airway epithelial cells has
not been reported. Therefore, this study was conducted in order to investigate the effect and the brief signaling
pathway of visfatin on MUC8 and MUC5B expression in human airway epithelial cells.
Results: Visfatin significantly induced MUC8 and MUC5B expression. Visfatin significantly activated phosphorylation
of p38 MAPK. Treatment with SB203580 (p38 MAPK inhibitor) and knockdown of p38 MAPK by siRNA significantly
blocked visfatin-induced MUC8 and MUC5B expression.Visfatin significantly increased ROS formation. Treatment
with SB203580 significantly attenuated visfatin-induced ROS formation. Treatment with NAC (ROS scavenger) and
DPI (NADPH oxidase inhibitor) significantly attenuated visfatin-induced MUC8 and MUC5B expression. However,
treatment with NAC and DPI did not attenuate visfatin-activated phosphorylation of p38 MAPK. Visfatin significantly
activated the phosphorylation of NF-κB. Treatment with PDTC (NF-κB inhibitor) significantly attenuated visfatin-induced
MUC8 and MUC5B expression.
Conclusions: These results suggest that visfatin induces MUC8 and MUC5B expression through p38 MAPK/ROS/NF-κB
signaling pathway in human airway epithelial cells.
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Mucins, highly glycosylated proteins, are the major com-
ponents of mucus. Among the mucins, MUC8, MUC5B,
and MUC5AC are representative secretory mucin genes in
the human airway [1,2]. MUC8, MUC5B, and MUC5AC
expression is increased by a variety of inflammatory medi-
ators in airway inflammatory diseases such as chronic
bronchitis [3].
Among a variety of inflammatory mediators, visfatin is
a proinflammatory adipocytokine that is preferentially
produced by visceral adipose tissue: visfatin is highly
enriched in visceral fat and its expression level in plasma* Correspondence: ydkim@med.yu.ac.kr
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unless otherwise stated.increases during development of obesity [4,5]. Although
the biological role of visfatin is not entirely clear, visfatin
is known to have insulin-mimetic action because it re-
duces blood glucose level [6]. Several recent studies have
reported an association of visfatin with inflammation
and oxidative stress response: expression of visfatin is
upregulated during activation of immune cells such as
monocytes, macrophages, dendritic cells, T cells, and B
cells, as well as in amniotic epithelial cells upon stimula-
tion with lipopolysaccharide, TNF-α, IL-1β, or IL-6
[7-10]. And visfatin increases expression of inflammatory
adhesion molecules in vascular endothelial cells in ROS-
dependent manner through NF-κB signaling pathway
[5]. Therefore, it could be hypothesized that visfatin may
play a role in expression of mucin gene in human airway
epithelial cells. However, the biological role of visfatin in
secretion of major mucins in human airway epithelial
cells has not been reported. For the this reason, thistd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The effects of visfatin on MUC16, MUC8, MUC5B,
MUC5AC, and MUC4 expression in NCI-H292 cells. RT-PCR
showed that visfatin induced remarkable MUC8 and MUC5B mRNA
expression. However, visfatin did not definitely induce MUC16,
MUC5AC, and MUC4 mRNA expression. Images are representative
of three separate experiments performed in triplicate. Bars indicate
the mean ± S.D. of three independent experiments performed in
triplicate. *P < 0.05 compared with zero value.
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and the brief signaling pathway of visfatin on MUC8 and
MUC5B expression in human airway epithelial cells.
Methods
Materials
Visfatin was purchased from Biovision Inc. (Mountain
View, CA, USA). RT-PCR kits were obtained from Applied
Biosystems (Foster City, CA, USA). Real-time PCR kits
were obtained from Roche Applied Science (Mannheim,
Germany). Enhanced chemiluminescence kit was obtained
from Perkin Elmer Life Sciences (Boston, MA, USA).
ERK1/2, phospho-ERK1/2, p38, phospho-p38, NF-κB, and
phosphor-NF-κB were purchased from Cell Signaling
Technology (Danvers, MA, USA). The specific inhibitor,
U0126 was purchased from Calbiochem (San Diego, CA,
USA), SB203580 was purchased from BIOMOL (Plymouth
Meeting, PA, USA), and NAC, DPI, and PDTC were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). Prede-
signed siRNA targeting p38 MAPK, negative control
siRNA for p38 MAPK, OPTI-MEM I Reduced Serum
Medium, and Lipofectamine 2000 were purchased from
Invitrogen Corporation (Carlsbad, CA, USA).
For the primary culture, nasal mucosa was obtained
from normal inferior turbinate samples from 10 patients
undergoing augmentation rhinoplasty who had no per-
sonal or family history of allergy, and who had negative
results on skin-prick tests to 20 common airborne aller-
gens and on multiple simultaneous allergen tests. This
study was approved by the institutional review board for
human studies at the Yeungnam University Medical
Center and written informed consent was obtained from
each patient.
Cell culture and treatment
Human NCI-H292 airway epithelial cells (American
Type Culture Collection, Manassas, VA, USA) were cul-
tured in RPMI 1640 medium (Invitrogen Corporation)
supplemented with 2 mM L-glutamine, 100 U/mL peni-
cillin, 100 μg/mL streptomycin, and 10% fetal bovine
serum (Hyclone Laboratories, Logan, UT, USA). The
cells were grown at 37˚C in 5% CO2 fully humidified air
and subcultured twice weekly. When the cultures had
reached confluence, the cells were incubated in RPMI
1640 medium containing 0.5% fetal bovine serum for
24 h. The cells were then rinsed with serum-free RPMI
1640 medium and exposed to the indicated concentra-
tions of visfatin.
For the primary culture of human nasal epithelial cells,
the nasal mucosal tissue was washed with PBS and
immersed in dispase (Boehringer Mannheim Biochem-
ica, Mannheim, Germany) for 90 min. The tissue was
scraped off the surface of the nasal mucosa using a scal-
pel; it was then added to 1% PBS and filtered through amesh. The cells were seeded in a 24-well plate at 2.5 ×
105 cells/well, followed by incubation with EpiLife
medium (Cascade Biologics, Portland, OR, USA) and
human keratinocyte growth supplement (5 mL/500 mL
of medium, Cascade Biologics). When the cultures had
reached confluence, the cells were exposed to the indi-
cated concentrations of visfatin. To investigate the brief
signaling pathway of mucin gene expression, human
NCI-H292 airway epithelial cells and human nasal epi-
thelial cells were pretreated with U0126, SB203580,
PDTC, NAC, or DPI for 1 h before exposure to visfatin.
For the controls, human NCI-H292 airway epithelial
cells and human nasal epithelial cells were incubated
with the medium alone for the same amount of time.
RT-PCR and real time PCR analysis of MUC16, MUC8,
MUC5B, MUC5AC, and MUC4 mRNA expression
Total RNA was isolated from the cultured cells accord-
ing to the manufacturer’s instructions (Applied Biosys-
tems). Each sample was reverse transcribed into cDNA
using the GeneAmp RNA PCR Core Kit (Applied Biosys-
tems). The primer sequences and conditions used were ac-
cording to previously published protocols for MUC16,
MUC8, MUC5B, MUC5AC, and MUC4 [11,12]. The PCR
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stained with ethidium bromide, and visualized by UV
fluorescence. Semiquantitative analysis of the RT-PCR
product was performed on the scanned gel images, and
the intensity of the PCR product was measured using
commercially available imaging software (Scion, Frederick,
MD, USA). The relative intensity of the individual bands
on the gel image was determined as the ratio of the inten-
sities of each MUC16, MUC8, MUC5B, MUC5AC, and
MUC4 to the intensity of GAPDH.
Real-time PCR was performed using the LC Fast Start
DNA Master SYBR Green kit (Roche Applied Science)
using 0.5 μL of cDNA, corresponding to 25 ng of total
RNA in a 10 μL final volume, 2.5 mM MgCl2 and
0.5 μM of each primer (final concentration). Quantita-
tive PCR was performed using a LightCycler (Roche Ap-
plied Science) for 45 cycles at 95˚C for 10 s, specific
annealing temperature for 5 s and 72˚C for 10 s. Data
were normalized to GAPDH. Amplification specificity
was evaluated using a melting curve, following the man-
ufacturer’s instructions (Roche Applied Science).
ELISA analysis of MUC8 and MUC5B proteins
MUC8 and MUC5B protein levels were determined by
ELISA. Samples of supernatant or cell lysates from hu-
man NCI-H292 airway epithelial cells were prepared in
PBS at several dilutions, and each sample was incubatedFigure 2 The effects of visfatin on MUC8 MUC5B expression in NCI-H
significantly increased MUC8 and MUC5B expression: visfatin-induced MUC
expression, and MUC8 and MUC5B mRNA expression peaked at 8 h after tr
separate experiments performed in triplicate. Bars indicate the mean ± S.D.
compared with zero value.at 40˚C in a 96-well plate until dry. The plates were then
washed three times with PBS, blocked with 2% bovine
serum albumin for 1 h at room temperature, washed
again three times with PBS, and incubated with primary
antibody for MUC8 or MUC5B (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), followed by dilution at 1:200
with PBS containing 0.05% Tween 20 for 1 h. The wells
were then washed three times with PBS, horseradish
peroxidase-conjugated secondary antibody for MUC8 or
MUC5B (Santa Cruz Biotechnology) was dispensed into
each well. After 4 h, color was developed using 3,3’, 5,5’-
tetramethylbenzidine peroxidase solution and stopped
with 2 N-H2SO4. Optical density was measured at
450 nm using an ELISA reader (EL800; BIO-TEK Instru-
ments, Winooski, VT, USA).
Western blot analysis of p38 MAPK, ERK1/2 MAPK,
and NF-κB
Samples of cells from human NCI-H292 airway epithe-
lial cells were seeded in wells of a 6-well plate and
treated with visfatin. The cells were exposed to trypsin
and formed into pellets at 700 g at 4˚C pellets were re-
suspended in lysis buffer. The preparation was then clari-
fied by centrifugation, and the supernatant was saved as a
whole-cell lysate. Proteins (20 μg) were separated using
10% reducing sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and electroblotted onto a nitrocellulose292 cells. (A-D) Real time RT-PCR and ELISA showed that visfatin
8 expression was significantly stronger than visfatin-induced MUC5B
eatment with visfatin (300 ng/mL). Images are representative of three
of three independent experiments performed in triplicate. *P < 0.05
Figure 3 The phosphorylation of p38 MAPK in visfatin-induced
MUC8 and MUC5B expression in NCI-H292 cells. (A) Western blot
analysis showed that visfatin activated phosphorylation of p38 MAPK;
however, visfatin did not activate phosphorylation of ERK1/2 MAPK.
(B) RT-PCR showed that SB203580 inhibited visfatin-induced MUC8 and
MUC5B expression; however, U0126 did not inhibit visfatin-induced
MUC8 and MUC5B expression. (C) RT-PCR showed the knockdown of
p38 MAPK by siRNA significantly blocked visfatin-induced MUC8 and
MUC5B mRNA expression. Images are representative of three separate
experiments performed in triplicate. Bars indicate the mean ± S.D. of
three independent experiments performed in triplicate. *P< 0.05
compared with zero value. **P < 0.05 compared with visfatin alone,
†P< 0.05 compared with negative control.
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dry milk, followed by incubation with the indicated pri-
mary antibody for p38, ERK1/2, or NF-κB (Cell Signaling
Technology) for 4 h. Subsequently, the membrane was in-
cubated for 1 h with secondary antibody for p38, ERK1/2,
or NF-κB (Cell Signaling Technology) conjugated to
horseradish peroxidase, and developed using an enhanced
chemiluminescence kit. Bands were detected after expos-
ure to x-ray film for 10 s.
Cell transfection with siRNA for p38 MAPK
Sequences of each siRNA were as follows: p38 MAPK;
forward: AUG AAU GAU GGA CUG AAA UGG UCU
G and reverse: CAG ACC AUU UCA GUC CAU CAU
UCA U. The transfection rate of p38 MAPK siRNA was
verified to be over 90% in human NCI-H292 airway epi-
thelial cells. Transfection was performed according to
the manufacturer’s protocol (Invitrogen Corporation).
Briefly, the cells were seeded in wells of a 6-well plate at
1 × 105 cells/well and incubated in RPMI 1640 medium.
When the cells had reached confluence, OPTI-MEM I
Reduced Serum Medium was added. Then, p38 MAPK
siRNA and Lipofectamine 2000 were incubated together
in OPTI-MEM I Reduced Serum Medium to form a p38
MAPK siRNA-Lipofectamine complex. The p38 MAPK
siRNA-Lipofectamine complex-containing medium was
added to each well containing the cells to a final p38
MAPK siRNA concentration of 20 nM. After 24 h of
transfection with p38 MAPK siRNA, the cells were ex-
posed to the indicated concentrations of visfatin and
then harvested for RT-PCR analysis of MUC8 and
MUC5B mRNA expression. The same procedure was
performed with negative control siRNA: the cells were
transfected with Lipofectamine 2000 only in negative
control siRNA.
Flow cytometric measurement of ROS
Human NCI-H292 airway epithelial cells were loaded
with 50 μM 2,7-DCF-DA (Sigma-Aldrich) for 40 min,
and were then washed three times with PBS before they
were harvested. The washed cells were resuspended in
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analysis was started. Measurement of ROS formation
was performed immediately by flow cytometry using
FACSort (BD bioscience, Rutherford, NJ, USA) with a
488-nm excitation beam. The signals were obtainedFigure 4 The role of ROS in visfatin-induced MUC8 and MUC5B
expression in NCI-H292 cells. (A) Flow cytometry showed that
visfatin (300 ng/mL) significantly induced ROS formation, especially
after 2 h. (B) RT-PCR showed that both NAC and DPI significantly
attenuated visfatin-induced MUC8 and MUC5B mRNA expression.
Images are representative of three separate experiments performed
in triplicate. Bars indicate the mean ± S.D. of three independent
experiments performed in triplicate. *P < 0.05 compared with zero
value. **P < 0.05 compared with visfatin alone.using a 530-nm band-pass filter for 2,7-DCF-DA. Each
determination was based on the mean fluorescence in-
tensity of 5,000 cells.
Statistical analysis
Commercially available software (SPSS, version 10.0;
SPSS Inc, Chicago, IL, USA) was used in performance ofFigure 5 The role of ROS in visfatin-activated phosphorylation
of p38 MAPK in NCI-H292 cells. (A) Western blot showed that both
NAC and DPI did not attenuate visfatin-activated phosphorylation of
p38 MAPK. (B) Flow cytometry showed that SB203580 significantly
inhibited visfatin-induced ROS formation. Images are representative
of three separate experiments performed in triplicate. Bars indicate the
mean ± S.D. of three independent experiments performed in triplicate.
*P < 0.05 compared with zero value. **P < 0.05 compared with
visfatin alone.
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quantitative values was calculated. Comparisons were
made using the Student’s t-test. For all tests, a p value of
less than 0.05 was considered statistically significant.
Results
Visfatin induced MUC8 and MUC5B expression in
NCI-H292 cells
To investigate the effect of visfatin on MUC16, MUC8,
MUC5B, MUC5AC, and MUC4 expression in human
NCI-H292 airway epithelial cells, the cells were incu-
bated with different doses of visfatin for 8 h. Result of
RT-PCR showed remarkable visfatin-induced MUC8
and MUC5B mRNA expression: visfatin-induced MUC8
mRNA expression was significantly stronger than visfatin-
induced MUC5B mRNA expression. However, visfatin did
not definitely induce MUC16, MUC5AC, and MUC4
mRNA expression (Figure 1, P < 0.05). Real time RT-PCR
and ELISA analysis were performed to investigate the
effect of visfatin on MUC8 and MUC5B expression in
a dose- and time-dependent manner. The cells were
treated with different doses of visfatin for 8 h or visfatin
(300 ng/mL) for variable times. The results also showed a
significant increase in MUC8 and MUC5B mRNA expres-
sion and protein production by treatment with all dosages
of visfatin: visfatin-induced MUC8 expression was signifi-
cantly stronger than visfatin-induced MUC5B expression,
and MUC8 and MUC5B mRNA expression peaked at 8 h
after treatment with visfatin (300 ng/mL) (Figure 2A-D,
P < 0.05).
p38 MAPK was involved in visfatin-induced MUC8 and
MUC5B expression in NCI-H292 cells
To evaluate the brief intracellular mechanisms of visfatin-
induced MUC8 and MUC5B expression, ERK1/2, or p38Figure 6 The role of NF-κB in visfatin-induced MUC8 and MUC5B exp
visfatin significantly activated the phosphorylation of NF-κB. (B) RT-PCR sho
MUC5B mRNA expression. Images are representative of three separate expe
independent experiments performed in triplicate. *P < 0.05 compared withMAPK signaling pathways were investigated in order to
determine whether they were capable of activating MUC8
and MUC5B expression in human NCI-H292 airway
epithelial cells. Results of Western blot analysis showed
that visfatin activated phosphorylation of p38 MAPK;
however, visfatin did not activate phosphorylation of
ERK1/2 MAPK (Figure 3A, P < 0.05). To confirm ERK1/2,
or p38 MAPK signaling pathways in visfatin-induced
MUC8 and MUC5B expression, the cells were treated
with U0126 as a specific ERK1/2 inhibitor or SB203580 as
a p38 MAPK inhibitor for 1 h before exposure to visfatin
for 8 h. Results of RT-PCR showed that SB203580 inhib-
ited visfatin-induced MUC8 and MUC5B expression;
however, U0126 did not inhibit visfatin-induced MUC8
and MUC5B expression (Figure 3B, P < 0.05). In addition,
cell transfection with siRNA was performed in order to
confirm whether phosphorylation of p38 MAPK was asso-
ciated with visfatin-induced MUC8 and MUC5B mRNA
expression. Results of RT-PCR showed that the knock-
down of p38 MAPK by siRNA significantly blocked
visfatin-induced MUC8 and MUC5B mRNA expression
(Figure 3C, P < 0.05).
ROS was involved in visfatin-induced MUC8 and MUC5B
expression in NCI-H292 cells
To examine visfatin-induced ROS formation, human
NCI-H292 airway epithelial cells were preincubated
with redox-sensitive fluorescent dye 2,7-DCF-DA. Com-
pared with control, flow cytometry showed that visfatin
(300 ng/mL) significantly induced ROS formation, espe-
cially after 2 h (Figure 4A, P < 0.05). To investigate the
role of ROS in visfatin-activated phosphorylation of p38
MAPK in MUC8 and MUC5B expression, the cells were
pretreated with NAC as a ROS scavenger, or DPI as an
NADPH oxidase, for 1 h before exposure to visfatin.ression in NCI-H292 cells. (A) Western blot analysis showed that
wed that PDTC significantly attenuated visfatin-induced MUC8 and
riments performed in triplicate. Bars indicate the mean ± S.D. of three
zero value. **P < 0.05 compared with visfatin alone.
Figure 7 The effect of visfatin on MUC8 and MUC5B expression
in normal nasal epithelial cells. (A) RT-PCR showed that a significant
increase of MUC8 and MUC5B mRNA expression by treatment with all
dosages of visfatin. (B) RT-PCR showed that visfatin-induced MUC8 and
MUC5B mRNA expression were significantly attenuated by pretreatment
with SB203580 as a p38 MAPK inhibitor. Images are representative of
three separate experiments performed in triplicate. Bars indicate the
mean ± S.D. of three independent experiments performed in triplicate.
*P < 0.05 compared with zero value. **P< 0.05 compared with
visfatin alone.
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significantly attenuated visfatin-induced MUC8 and MUC5B
mRNA expression (Figure 4B, P < 0.05). However, results
of Western blot showed that neither NAC nor DPI attenu-
ated visfatin-activated phosphorylation of p38 MAPK
(Figure 5A, P < 0.05). To confirm the correlation between
p38 MAPK and ROS, the cells were pretreated with
SB203580, as a specific inhibitor of p38 MAPK, 1 h before
exposure to visfatin. Flow cytometry showed that
SB203580 significantly attenuated visfatin-induced ROS
formation (Figure 5B, P < 0.05).
NF-κB was involved in visfatin-induced MUC8 and MUC5B
expression in NCI-H292 cells
Western blot analysis was performed to investigate the
effect of visfatin on NF-κB. Human NCI-H292 airway
epithelial cells were treated with visfatin. The results
showed that visfatin significantly activated the phosphor-
ylation of NF-κB (Figure 6A, P < 0.05). To investigate the
role of NF-κB in visfatin-induced MUC8 and MUC5B
expression, the cells were pretreated with PDTC as an
inhibitor of NF-κB for 1 h before exposure to visfatin.
Results of RT-PCR showed that PDTC significantly
attenuated visfatin-induced MUC8 and MUC5B mRNA
expression (Figure 6B, P < 0.05).
Visfatin induced MUC8 and MUC5B expression via p38
MAPK in primary cultures of normal nasal epithelial cells
To investigate the effect of visfatin on MUC8 and
MUC5B expression in primary cultures of normal nasal
epithelial cells, the cells were incubated with different
doses of visfatin for 8 h. Results of RT-PCR showed
a significant increase in MUC8 and MUC5B mRNA
expression by treatment with all dosages of visfatin
(Figure 7A, P < 0.05), and SB203580 as a p38 MAPK in-
hibitor significantly attenuated visfatin-induced MUC8
and MUC5B mRNA expression (Figure 7B, P < 0.05).
Discussion
Visfatin, a 52-kDa protein, was previously identified as a
PBEF. PBEF is secreted by human peripheral blood lym-
phocytes, and acts like a nicotinamide phosphoribosyl
transferase, which is involved in nicotinamide adenine
dinucleotide biosynthesis and is related to glucose and
lipid metabolism in humans [13,14]. PBEF was recently
found in high levels in visceral fat, and was renamed vis-
fatin. The biological roles of visfatin include an insulin
mimetic effect, cytokine and immunomodulator, enzyme,
and anti-apoptotic effect. As an immunomodulator,
visfatin induces dose-dependent up-regulation of the
pro- and anti-inflammatory cytokines, IL-1β, IL-6, IL-10,
and TNF-α in human monocytes: visfatin is associated
with sepsis, acute lung disease, atherosclerosis, and can-
cer [13,15]. However, the biological role of visfatin insecretion of major mucins in human airway epithelial
cells has not been reported. Therefore, it could be hy-
pothesized that visfatin may play a role in mucin gene
expression in human airway epithelial cells. This study
was conducted in order to determine whether visfatin
might regulate expression of the major secretory airway
mucin genes in airway epithelial cells. The results of this
study showed that visfatin significantly increased MUC8
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induce MUC16, MUC5AC, and MUC4 mRNA expression.
These results suggest that visfatin has up-regulation of
MUC8 and MUC5B expression, like an inflammatory medi-
ator: lipopolysaccharide, TNF α, and IL-1β.
Within the signaling pathway, visfatin induces vascular
endothelial growth factor, and production of matrix metal-
loproteinases via MAPK [8,16]. In addition, MUC8 or
MUC5B expression is induced in response to a wide variety
of stimuli, including nerve activation and inflammatory cy-
tokines, such as IL-1β, IL-6, TNF-α, and prostaglandin E2
through a process involving p38 or ERK1/2 MAPK activa-
tion [11,17,18]. And insulin-like growth factor-1, which has
an insulin mimetic effect like visfatin, induces MUC8 and
MUC5B expression via ERK1 and p38 MAPK signaling
pathway in human airway epithelial cells [19]. Therefore,
this study focused on visfatin-induced MUC8 and MUC5B
expression via the p38 or ERK1/2 MAPK signaling path-
way. The results of this study showed that visfatin acti-
vated phosphorylation of p38 MAPK. SB203580 inhibited
visfatin-induced MUC8 and MUC5B expression. In
addition, the knockdown of p38 MAPK by siRNA signifi-
cantly blocked visfatin-induced MUC8 and MUC5B
mRNA expression. These results suggest that visfatin in-
duces MUC8 and MUC5B expression through the p38
MAPK signaling pathway in human airway epithelial cells.
ROS produced by cytokines, growth factors, and va-
soactive agents contribute to the intracellular signaling
cascades associated with inflammatory responses. ROS in-
duce NF-κB activation by modifying the activity of one or
more of the kinase enzymes in the NF-κB activation cas-
cades [5]. Recent studies have reported that visfatin in-
creases expression of inflammatory adhesion molecules
through an ROS-dependent NF-κB signaling pathway in
vascular endothelial cells [5,7,9,16,20]. Therefore, this
study focused on correlation between visfatin-induced
MUC8 and MUC5B expression and ROS formation via
the NF-κB signaling pathway in human airway epithelial
cells. The results of this study showed that visfatin signifi-
cantly induced ROS formation. Treatment with SB203580
significantly attenuated visfatin-induced ROS formation.
Treatment with NAC and DPI significantly attenuated
visfatin-induced MUC8 and MUC5B expression. However,
neither NAC nor DPI attenuated visfatin-activated phos-
phorylation of p38 MAPK. Visfatin significantly activated
the phosphorylation of NF-κB. PDTC significantly attenu-
ated visfatin-induced MUC8 and MUC5B expression.
These results suggest that visfatin induces MUC8 and
MUC5B expression through the p38 MAPK/ROS/NF-κB
signaling pathway in human airway epithelial cells.
Conclusions
In summary, the results of this study demonstrate for
the first time that visfatin induces MUC8 and MUC5Bexpression in human airway epithelial cells. In addition,
visfatin-induced MUC8 and MUC5B expression may be
regulated through the p38 MAPK/ROS/NF-κB signaling
pathway in human airway epithelial cells. These results
provide important information demonstrating that modu-
lation of visfatin may be an appropriate pharmacological
target for control of mucus-hypersecretion in treatment of
airway inflammatory diseases in patients with obesity.
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